Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

INTRODUCTION: The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab versus sorafenib as a first-line treatment in younger versus older patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Daneng, Toh, Han Chong, Merle, Philippe, Tsuchiya, Kaoru, Hernandez, Sairy, Verret, Wendy, Nicholas, Alan, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801180/
https://www.ncbi.nlm.nih.gov/pubmed/36589722
http://dx.doi.org/10.1159/000525671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801180/
https://www.ncbi.nlm.nih.gov/pubmed/36589722
http://dx.doi.org/10.1159/000525671

Ejemplares similares